Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO ASSESS EFFICACY AND SAFETY OF OMECAMTIV MECARBIL IN PATIENTS WITH SYMPTOMATIC HEART FAILURE WITH SEVERELY REDUCED EJECTION FRACTION

Intervention/treatment:
OMECAMTIV MECARBIL
Medical condition:
HEART FAILURE
Protocol code:
CY 1033
Control number:
294209
Status:
Recruiting
Approved:
February 13, 2025
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT06736574
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 85 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Cytokinetics MD
Role
CONTACT
Phone:
(650) 624-2929
Sponsor
CYTOKINETICS, INCORPORATED

Locations

Alberta

Mazankowski Alberta Heart Institute / University of Alberta Hospital
Edmonton, Alberta, T6G2B7
RECRUITING

British Columbia

Kelowna General Hospital
Kelowna, British Columbia, V1Y1T2
RECRUITING
SMH - Cardiology Clinical Trials Inc.
Surrey, British Columbia, V3V0C6
RECRUITING
St. Paul's Hospital
Vancouver, British Columbia, V6Z1Y6
RECRUITING
Victoria Heart Institute Foundation
Victoria, British Columbia, V8R1B2
RECRUITING

Manitoba

St. Boniface Hospital
Winnipeg, Manitoba, R2H2A6
RECRUITING

Ontario

Kingston Health Sciences Centre
Kingston, Ontario, K7L 2V7
RECRUITING
London Health Sciences Centre
London, Ontario, N6A5A5
RECRUITING
Oakville Trafalgar Memorial Hospital - Halton Healthcare
Oakville, Ontario, L6M0L8
RECRUITING
St. Michael's Hospital
Toronto, Ontario, M5B1W8
RECRUITING
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N1J7
RECRUITING
UHN-Toronto General Hospital
Toronto, Ontario, M5G2C4
RECRUITING

Quebec

CISSSL - Hopital Pierre-Le Gardeur
Terrebonne, Quebec, J6V 2H2
RECRUITING
Diex Recherche Sherbrooke
Sherbrooke, Quebec, J1L0H8
WITHDRAWN
Montreal Heart Institute
Montreal, Quebec, H1T1C8
RECRUITING
Did you find what you were looking for?